BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Arriola E, Taus &, Casadevall D. Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? World J Clin Oncol 2015; 6(4): 45-56 [PMID: 26266101 DOI: 10.5306/wjco.v6.i4.45]
URL: https://www.wjgnet.com/2218-4333/full/v6/i4/45.htm
Number Citing Articles
Anne Winther-Larsen, Joan Fledelius, Boe Sandahl Sorensen, Peter Meldgaard. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinibLung Cancer 2016; 94: 81 doi: 10.1016/j.lungcan.2016.01.024
D. Debieuvre, L. Moreau, M. Coudert, C. Locher, B. Asselain, D. Coëtmeur, C. Dayen, F. Goupil, F. Martin, P. Brun, G. De Faverges, P.-A. Hauss, S. Gally, B. Ben Hadj Yahia, M. Grivaux. Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l’EGFR : données en vie réelleRevue des Maladies Respiratoires 2019; 36(6): 649 doi: 10.1016/j.rmr.2019.03.010
Carolina Somarriva, Alejandra Fernández, Jorge Candia, Javier Campos, Daniela Albers, Jorge Briceño. Dysregulation and detection methods of EGFR in oral cancer. A narrative review.Journal of Oral Research 2016; 5(7): 285 doi: 10.17126/joralres.2016.057
Anne Winther-Larsen, Joan Fledelius, Christina Demuth, Catharina M Bylov, Peter Meldgaard, Boe S Sorensen. Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC PatientsTranslational Oncology 2016; 9(6): 505 doi: 10.1016/j.tranon.2016.09.003